AstraZeneca is advancing plans to exit production in India by giving up its manufacturing license in the country some two ...

The UK is losing business opportunities in the life sciences sector because the government undervalues the economic and ...

BD is putting a fresh spin on an old awareness drive, returning to the 12-year-old “Love Your Limbs” campaign to mark ...

Amid ongoing upheaval at the FDA and other federal health agencies, prominent vaccine expert and Robert F. Kennedy Jr. critic ...

A new campaign from Aflac aims to be more than just a one-off awareness push. | The “Check for Cancer” campaign, which ...

It hasn’t been an obvious linear path,” Morgan Biles says about the road that has led to her current position as a senior ...

United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

More than three years after launching a new corporate structure, Novartis is still making changes to its organization. | More than three years after launching a new corporate structure, Novartis is ...

Verquvo failed to deliver a composite cardiovascular benefit for certain patients with heart failure, with investigators noting seemingly divergent results on two key measures.

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

German generics maker Stada has settled on a buyout by CapVest Partners, putting an end to its previously reported IPO ambitions. | After musing a fall IPO just last week, Stada is instead being ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...